42 results about "Joint synovium" patented technology

The present application belongs to the technical field of medicine, and particularly relates to the use of tetrahydrojatrorrhizine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that tetrahydrojatrorrhizine can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis. Blood routine analysis shows that the administration of tetrahydrojatrorrhizine reduces the number of immune cells in the blood and weakens the immune level of the body. In addition, the experimental results also show that tetrahydrojatrorrhizine can inhibit synovial hyperplasia and relieve joint damage. Therefore, tetrahydrojatrorrhizine has the prospect of being developed into an oral medicament for treating rheumatoid arthritis, provides more treatment options for clinically treating rheumatoid arthritis, and has important social and economic values.

The invention discloses a lindera glauca extract, a preparation method thereof and application of the lindera glauca extract in preparation of drugs for preventing and / or treating rheumatoid arthritis. The research finds that the lindera glauca extract can obviously reverse arthritic rat plantar part swelling and toe bending, relieve ankle joint injury, relieve synovial hyperplasia and inflammatory cell infiltration, inhibit joint fusion, relieve joint gap stenosis, relieve articular surface fusion tendency, increase bone mineral density and bone trabecula number, reduce bone trabecula separation degree and improve joint fusion. The lindera glauca extract can be used for relieving rheumatoid arthritis by protecting the inherent structure of joint tissues and improving inflammation, so that a novel natural medicine choice is provided for preventing and / or treating rheumatoid arthritis.

The invention belongs to the technical field of biomedicine, and particularly relates to WTAP as a clinical diagnosis marker for rheumatoid arthritis and application of the WTAP. Experiments prove that the WTAP level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably higher than that of normal people, the WTAP and the rheumatoid arthritis are positively correlated, and the WTAP gene or WTAP protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the rheumatoid arthritis; the CIA mouse with the WTAP gene knocked out shows that the illness state is relieved, and the symptoms are relieved, so that the WTAP can be used as an effective target for treating rheumatoid arthritis.

The invention belongs to the technical field of medicines, and particularly relates to application of BAY-069 in preparation of a medicine for treating rheumatoid arthritis. Through metabonomics research, the inventor finds that the metabolic enzyme BCAT2 is remarkably highly expressed in synovial tissues of an active-stage RA patient and is relatively low in expression in synovial tissues of a remission-stage RA patient. The high expression of the metabolic enzyme BCAT2 is closely related to synovitis and bone destruction. The BAY-069 as a BCAT2 inhibitor can significantly reduce the score of joint inflammation, reduce synovitis and bone destruction, and effectively reduce bone loss. The invention provides an innovative RA metabolism targeted treatment strategy which has high safety and strong targeting property.

The invention relates to the technical field of arthritis treatment jackets, in particular to a rheumatoid arthritis hand auxiliary treatment jacket which comprises a glove, the glove is divided into a palm face and a hand back face, a wrist is constructed on one side of the glove, and a pressure control piece is arranged on the glove; the pressure control part comprises a cavity constructed in the glove, the cavity divides the glove into an outer layer and an inner layer, the outer layer is made of a heat preservation material, and the inner layer is made of an elastic material; a water injection valve communicated with the cavity is arranged on the glove, and liquid is allowed to enter and exit from the cavity by opening and closing the water injection valve; the three pressure control modes of wrist air bag pressurization and hand movement dynamic pressurization are adjusted through the liquid medicine injection amount, a patient can autonomously select pressure gears according to the illness state and the scene, low-gear mild pressurization is conducted during daily office mild movement, slight aching pain is relieved, operation is not affected, middle-gear moderate pressurization is conducted when joint swelling pain is aggravated, and therefore the patient can feel more comfortable. During night rest, middle and low gears can be flexibly selected, and morning stiffness is relieved while constraint feeling is avoided.

The invention relates to the technical field of biological medicine, in particular to application of a TRADD related reagent in rheumatoid arthritis related products. The invention finds that a TNFR1 signal channel is obviously enhanced in RA synovial tissues, and the expressions of TNFR1, TRAF2, TRADD and p65 are higher than those of normal synovial tissues, so that the invention provides the application of the reagent for detecting the expression of TRADD in the preparation of detection products for rheumatoid arthritis.

The application belongs to the technical field of natural medicinal chemistry, and relates to the use of a dibenzazepine compound in mistletoe in the preparation of a medicine for preventing or treating rheumatoid arthritis. In vitro experiments show that the use of the compound alone has different degrees of inhibitory effect on the proliferation of primary rat synovial fibroblasts, and the inhibitory effect is synergistically enhanced when the compound 2 is used in combination with mistletoe lectin. Animal experiments show that the use of the compound alone has different degrees of inhibitory effect on the joint swelling of a collagen-induced rat arthritis model, and the inhibitory effect of some dibenzazepine compounds is close to or better than that of a positive medicine, and the inhibitory effect of the compound 2 used in combination with mistletoe lectin on the joint swelling of the right hind foot of a rat is synergistically enhanced. In summary, the dibenzazepine compound in mistletoe has the potential to be developed into a medicine for treating rheumatoid arthritis, can provide more choices for clinical treatment, and has important social benefits and economic value.

The invention relates to the field of traditional Chinese medicines, in particular to an active pharmaceutical ingredient for preventing and treating rheumatoid arthritis and a preparation method thereof. The traditional Chinese medicine extract, namely coix seed ester, disclosed by the invention has the effects of preventing and treating pain, numbness and soreness of limbs, joints, muscles and the like due to arthralgia syndromes as well as adverse flexion and extension, swelling and deformation of the joints and the like. Animal experiment research proves that the coix seed ester has a good improvement effect on treating a rat model with arthritis induced by collagen, and the coix seed ester can obviously inhibit synovial hyperplasia and formation of vascular nebula and inhibit inflammatory response of RA (rheumatoid arthritis). The idea of treating the RA by using the coix seed ester is based on the pathogenesis of phlegm-dampness formation in the traditional Chinese medicine theory and the inflammation mechanism of modern research, the traditional Chinese medicine and the western medicine are combined, and the important clinical significance is achieved for relieving the pain of patients and improving the life quality.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.

The application discloses application of a medicine composition in preparation of a medicine for treating rheumatoid arthritis (RA), and belongs to the field of RA treating medicines. The medicine composition is composed of swertiamarin (SW) and neochlorogenic acid (NCA) and is screened from two active ingredients in Danteng Yimu Decoction. With the help of animal model and cell model experiments, the action mechanism of the medicine composition in treating RA is explored, the related symptoms and indexes of collagen-induced arthritis (CIA) rats can be effectively improved, joint swelling can be relieved, arthritis inflammation index can be reduced, inflammatory factor release can be inhibited, joint bone quality can be protected, arthritis inflammation infiltration and cartilage destruction can be reduced, and the medicine safety is good. The composition can effectively inhibit the inflammatory factor release and migration ability of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). Animal experiments and cell experiments prove that the combination of neochlorogenic acid and swertiamarin (SW+NCA) can be effectively applied to clinical treatment of RA and has a wide application prospect.

The invention discloses a multi-modal data fusion-based rheumatoid arthritis early-stage AI intelligent diagnosis system, belongs to the technical field of medical artificial intelligence, and aims to solve the problems that in the prior art, RA early-stage diagnosis lags behind, the rate of missed diagnosis of serum negative patients is high, and risk assessment lacks quantitative standards. Comprising a multi-source data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic time sequence model and a risk assessment module which are connected in sequence, according to the system provided by the invention, a dynamic tracking model of serological change-synovial inflammation-bone structure change is innovatively constructed, and an RA diagnosis window is advanced compared with that of a traditional method (depending on clinical symptoms) by capturing time sequence correlation of the serological change, the synovial inflammation and the bone structure change; aiming at the diagnosis difficulty of serum-negative RA, the system realizes great improvement of diagnosis performance through deep fusion of multi-modal features, serological core indexes, ultrasonic synovial dynamic features and X-ray bone microscopic features.

To provide novel drugs effective in improving pain associated with osteoarthritis of the knee and periarthritis of the shoulder. [Solution] According to the present invention, a synovial pain reliever for arthritis is provided, comprising an endothelin A receptor antagonist as an active ingredient, wherein the arthritis is osteoarthritis of the knee or periarthritis of the shoulder. According to the present invention, it is possible to improve joint pain caused by movements that put a load on the knee joint and joint pain at rest in patients with osteoarthritis of the knee, and it is possible to improve joint pain caused by movements that put a load on the shoulder joint and joint pain at rest in patients with periarthritis of the shoulder.

The application discloses application of myrtenal in preparation of a medicine for preventing and / or treating rheumatoid arthritis. The application verifies for the first time that myrtenal can block the RA inflammatory cascade from multiple aspects, and overcomes the limitation that single-target treatment is easy to produce drug resistance. Specifically, myrtenal can reduce the levels of inflammatory factors and metal proteins; inhibit the proliferation, migration and invasion of synovial fibroblasts SFs; inhibit the expression of glycolysis-related genes, reduce sugar metabolites; inhibit the synovial tissue hyperplasia, inflammatory cell infiltration, bone erosion and bone destruction of mice joints; promote the mental state of arthritis mice to be obviously improved, the food intake to be increased, the hair to be shiny, the joint swelling to be subsided, the bruise of the ankle joint to be subsided, the skin to be improved, and the activity to be sensitive. Therefore, the application proposes a new medical use of myrtenal in treating rheumatoid arthritis, and develops a brand-new therapeutic indication of myrtenal.

The application discloses a kind of nanomedicine for treating rheumatoid arthritis, including triptolide, Y6 fluorescent probe and poloxamer, triptolide and Y6 fluorescent probe are polymerized by poloxamer to form triptolide nanomedicine Y6@TPL, the average particle size of the triptolide nanomedicine Y6@TPL is 20~300nm.The application combines triptolide with Y6 fluorescent probe, constructs a new type of nano delivery system, the system not only realizes the accurate control release of drug, but also can be enhanced by photo-thermal response Targeted accumulation of rheumatoid arthritis lesion site, significantly improve the selective killing effect of triptolide on inflammatory synoviocytes, while greatly reducing the toxic side effects on normal joint tissue.The nano system integrates photo-thermal therapy, photo-thermal imaging and targeted drug delivery functions, and provides an integrated solution for the diagnosis and treatment of RA.

The invention discloses a nano-drug for treating rheumatoid arthritis, the nano-drug comprises triptolide, a Y6 fluorescent probe and poloxamer, the triptolide and the Y6 fluorescent probe are polymerized by the poloxamer to form a triptolide nano-drug Y6 at TPL, and the average particle size of the triptolide nano-drug Y6 at TPL is 20-300 nm. The triptolide and the Y6 fluorescent probe are combined to construct a novel nano delivery system, the system not only realizes precise controlled release of drugs, but also can enhance targeted accumulation of rheumatoid arthritis focus parts through photo-thermal response, the selective killing effect of the triptolide on inflammatory synovial cells is remarkably improved, and the application prospect is broad. Meanwhile, the toxic and side effects on normal joint tissues are greatly reduced. According to the nano system, photo-thermal treatment, photo-thermal imaging and targeted drug delivery functions are integrated, and an integrated solution is provided for diagnosis and treatment of RA.

Disclosed herein are various bioreactor devices that mimic the mammalian joint. The bioreactor device includes a series of bioreactor chambers that contain different components of the joint, such as bone, cartilage, synovium, and ligament, and which are integrated with neural processes to better recapitulate physiological conditions, including joint pain. At least two different nutrient fluid circulation systems connect subsets of the bioreactor chambers to differentially supply nutrient fluids at concentrations optimized for the tissue that the fluid nourishes. The disclosed bioreactor devices enable interrogation of the interplay between the peripheral nervous system and joint tissues. By recording activity in sensory neurons, joint integrity as well as therapeutic efficacy can be monitored in real time.

The invention discloses a Jinhuang powder external application paste and application thereof in preparation of drugs for treating gonitis synovitis, the external application paste is prepared from ten traditional Chinese medicines including turmeric, rheum officinale, golden cypress, radix angelicae, rhizoma arisaematis, pericarpium citri reticulatae, rhizoma atractylodis, mangnolia officinalis, liquorice and radices trichosanthis, honey, edible vegetable oil, paraffin oil and water through a specific emulsification process, the pH value is 6.0-7.0, and the viscosity is 3000-5000 mPa.s; standard random control clinical tests prove that the total effective rate of the external application ointment for treating gonarthromeningitis reaches 99.04%, the Lyshilm score is improved by 30.2 score, the VAS score is reduced by 5.39 score and is greatly superior to that of a diclofenac sodium control group, the adverse reaction occurrence rate is only 3.85%, the levels of serum TNF-alpha, IL-1beta and IL-6 and the synovial thickness can be greatly reduced, and the external application ointment has a good clinical application prospect. The method is suitable for K-L grading I-II and postoperative rehabilitation patients.

The invention discloses an application of rotigotine microspheres in preparation of medicines for preventing or treating rheumatic arthritis, the rotigotine microspheres can directly act on joint parts, joint synovial hyperplasia, joint injury and bone erosion are effectively reduced, and the curative effect of the rotigotine microspheres is improved. The rotigotine microspheres can be independently used or matched with other known medicines, compounds or carriers to be prepared into various forms of medicaments or pharmaceutical compositions for prevention or treatment, and the dopamine receptor can be continuously excited for 4-8 weeks by injecting once during administration, so that the'on-off 'phenomenon caused by fluctuation of blood concentration is remarkably improved, and the bioavailability of the rotigotine microspheres is improved. Therefore, the curative effect can be effectively improved, and the compliance of a patient is greatly improved.

The invention provides methods and products to reduce one or more symptoms from injury to a synovial joint. The methods and products relate to injecting into or around cartilage of the synovial joint the peptide GsMTx4 or a composition targeting GsMTx4 to the cartilage. The synovial joint can be, for example, a knee joint, shoulder joint, hip joint, or a facet joint of the spine.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of psoralen in the preparation of drugs for the prevention and treatment of rheumatoid arthritis. This invention aims to address the problem of insufficient efficacy and inadequate clinical needs of existing rheumatoid arthritis prevention and treatment drugs, filling the technological gap in the pharmacological activity of psoralen against rheumatoid arthritis. Studies have confirmed that psoralen can effectively inhibit the secretion of IL-6 and IL-8 by RA-FLS cells, effectively inhibit RA-FLS cell proliferation, migration, and invasion, significantly improve joint swelling and weight loss symptoms in CIA mice, effectively regulate immune imbalance, and effectively repair joint pathological damage. It blocks the pathological processes of rheumatoid arthritis, including inflammation, immune disorders, synovial damage, and bone destruction, from multiple pathways and dimensions. Furthermore, psoralen is a natural plant-derived component. This invention provides a novel natural drug option for the treatment of rheumatoid arthritis, effectively improving the existing treatment system for the disease.

The application provides application of SEMA3E protein in preparation of a drug for treating rheumatoid arthritis and promoting cartilage regeneration, and belongs to the technical field of biological medicine. The amino acid sequence of the SEMA3E protein is shown as SEQ ID No. 1. Research results show that one month after injection of the SEMA3E protein solution, the joint swelling degree of the double hind limbs of an animal model is reduced, the joint space and integrity are restored to normal, the cartilage thickness is increased, and the phenomenon of synovial cell infiltration and invasion into the cartilage is eliminated. That is, the SEMA3E protein can well reduce joint cavity inflammation and improve damaged joints.

The application discloses a method for constructing a spontaneous rheumatoid arthritis animal model, and the rheumatoid arthritis phenotype of the mouse is spontaneously generated by knocking out PPARgamma in the skin keratinocytes of the joint part, including joint swelling, joint synovial thickening, inflammatory cell infiltration, anti-cyclic citrullinated polypeptide antibody increase, and rheumatoid factor increase, so that the clinical symptoms of the rheumatoid arthritis are simulated, and an important tool is provided for the related research of the rheumatoid arthritis.

The invention discloses a traditional Chinese medicine composition for treating rheumatoid arthritis osteolysis and application thereof. The traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 6 to 12 parts of rhizoma curculiginis (roasted with wine), 9 to 15 parts of herba epimedii, 6 to 12 parts of radix clematidis, 10 to 15 parts of radix angelicae sinensis, 9 to 15 parts of radix achyranthis bidentatae, 6 to 15 parts of fructus lycii and 2 to 10 parts of liquorice root. The traditional Chinese medicine composition has the effects of synergistically warming and invigorating kidney yang and strengthening muscles and bones, can reduce expression of inflammatory factors TNF-alpha, IL-6 and IL-1beta in plasma of mice with collagen-induced arthritis (CIA), reduces inflammatory cell infiltration in synovial tissues, remarkably reduces the number of osteoclasts and erosion progress, and is good in safety.

The invention provides application of a composition in treatment of knee osteoarthritis. According to the invention, two rat knee osteoarthritis models (the former is called as an ACLT-induced KOA model for short, and the latter is called as a papain-induced KOA model for short) are established by respectively utilizing methods of combining anterior cruciate ligament transection (ACLT) with running and injecting papain composite L-cysteine into an articular cavity; the composition provided by the invention is used for treating two rat KOA models. Results show that the composition can improve knee joint swelling of two KOA rats, increase the pain threshold, improve the abnormal gait state, relieve cartilage injury, inhibit ACLT-induced abnormal change of a KOA rat knee joint subchondral bone microstructure and papain-induced PGE2 content in KOA rat synovial tissue, and can be used for preparing a medicine for treating osteoporosis. The level of inflammatory factors in serum and joint lavage fluid of the two KOA rats is reduced, and the discovery shows that the KOA has important application in treatment of knee osteoarthritis.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

The invention belongs to the technical field of medicines, and particularly relates to application of BCAT2 as a target spot in preparation of a medicine for treating rheumatoid arthritis. Through metabonomics research, the inventor finds that the metabolic enzyme BCAT2 is remarkably highly expressed in synovial tissues of an active-stage RA patient and is relatively low in expression in synovial tissues of a remission-stage RA patient. The high expression of the metabolic enzyme BCAT2 is closely related to synovitis and bone destruction. The BCAT2 inhibitor (telmisartan) can significantly reduce joint inflammation score, reduce synovitis and bone destruction, and effectively reduce bone loss. The invention provides an innovative RA metabolism targeted treatment strategy which has high safety and strong targeting property.

The invention relates to application of limonin in preparation of a medicine for resisting rheumatoid arthritis chronic pain, and belongs to the technical field of medicine application. In order to solve the problem that the existing medicine for treating the chronic pain of rheumatoid arthritis is difficult to control, the invention provides application of limonin in preparation of the medicine for treating the chronic pain of rheumatoid arthritis, and the limonin serves as an active ingredient in the medicine for treating the chronic pain of rheumatoid arthritis. The limonin is used for preparing the medicine for resisting the rheumatoid arthritis chronic pain, wherein the medicine intervenes the functions of rheumatoid arthritis synovial fibroblasts through a histamine H4R mediated mechanism. The traditional Chinese medicine can effectively solve the persistent chronic pain caused by rheumatoid arthritis, and has the advantage of good curative effect.

The application provides a Chinese medicine composition containing Notopterygium incisum and Lonicera japonica in preparation and treatment of rheumatoid arthritis, and belongs to the technical field of medicine; scientific research shows that the Chinese medicine composition containing Notopterygium incisum and Lonicera japonica can reduce joint cartilage destruction, subchondral bone destruction caused by rheumatoid arthritis, promote osteoblast differentiation and mineralization, reduce joint swelling, synovial hyperplasia, and inflammatory cell infiltration of joints caused by rheumatoid arthritis, has the effect of treating rheumatoid arthritis, and can be developed into a medicine for treating rheumatoid arthritis.

The present invention belongs to the field of medical technology, and specifically relates to the use of corydaline or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that corydaline can effectively alleviate the level of paw swelling in CIA rats, reduce arthritis scores, and inhibit the progression of rheumatoid arthritis. Routine blood analysis shows that administration of corydaline reduces the number of immune cells in the blood and weakens the body's immune level. In addition, experimental results also show that corydaline can inhibit synovial hyperplasia and alleviate joint damage. Therefore, corydaline has the prospect of being developed into an oral medication for treating rheumatoid arthritis, providing more treatment options for the clinical treatment of rheumatoid arthritis, and has important social benefits and economic value.